BioSpace News Archive

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the first patient has been dosed with NTLA-5001, the company’s ex vivo CRISPR/Cas9 genome editing candidate for the treatment of acute myeloid leukemia (AML).

NeuroGenesis and Hadassah Medical Center announced today positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of NG-01 autologous proprietary subpopulation of bone marrow cells on the expression levels of NF-L.

Quanterix Corporation today announced it has entered into a collaboration with Eli Lilly and Company (Lilly) to advance the diagnosis, monitoring and treatment of Alzheimer’s disease.

Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel for the treatment of patients with advanced pancreatic cancer in the first-line setting (NCT05239182).

Oculogica, a leader in concussion diagnostics, today announced launch of the new EyeBOX device following FDA clearance earlier this year.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the 32nd Annual Oppenheimer Healthcare Conference.

Inari Medical, Inc. a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the appointment of Mr. Robert Warner to its board of directors.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 42nd Annual Cowen Health Care Conference, taking place March 7-9, 2022.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be participating in upcoming investor and scientific conferences.

Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced financial results for the fourth quarter and fiscal year ended December 31, 2021.